Adverse effects of tenofovir use in HIV-infected pregnant women and their infants

Diana Nurutdinova, Nur F. Onen, Ericka Hayes, Kristin Mondy, E. Turner Overton

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

BACKGROUND: Data regarding use of tenofovir disoproxil fumarate in HIV-infected pregnant women are limited. OBJECTIVE: To identify adverse effects of tenofovir use during pregnancy in HIV-infected women and their infants. METHODS: In a retrospective case series, the charts of 127 pregnant HIV-infected women who received highly active antiretroviral therapy (HAART) between 2001 and 2005 were reviewed. Those who received tenofovir during pregnancy were selected for this study. Each woman's chart was reviewed for clinical data and adverse events during the pregnancy; each infant's chart was reviewed for growth parameters from birth to 12 months. RESULTS: Fifteen HIV-infected women with limited treatment options were prescribed HAART containing tenofovir during 16 pregnancies. In utero tenofovir exposure was a median of 127 days (range 6-259). Tenofovir was well tolerated by all women throughout pregnancy. There were 15 successful deliveries occurring at a median (range) of 36 weeks (30-40), with a median birth weight of 3255 g (1135-3610). Complications, including 1 spontaneous abortion, occurred in 9 pregnancies and were not attributed to tenofovir. Eleven (73%) women had abnormal laboratory results, including 6 who experienced grade 1 hemoglobin abnormalities: 4 of these women had preexisting anemia. Calculated glomerular filtration rate (calculated by Modification of Diet in Renal Disease equation) remained above 90 mL/min/1.73 m2 in all women, except one who had a transient decline. Fourteen infants demonstrated normal growth and development for weight and height at birth, as well as during the 12-month follow-up period; no congenital malformations were documented. Mother-to-child transmission of HIV was not observed in this cohort. CONCLUSIONS: Tenofovir was found to be a well-tolerated component of HAART in this small cohort. Longer-term assessment of tenofovir effects on childhood growth and larger prospective studies of tenofovir use in pregnant women are warranted.

Original languageEnglish (US)
Pages (from-to)1581-1585
Number of pages5
JournalAnnals of Pharmacotherapy
Volume42
Issue number11
DOIs
StatePublished - Nov 2008

Fingerprint

Tenofovir
Pregnant Women
HIV
Pregnancy
Highly Active Antiretroviral Therapy
Parturition
Diet Therapy

Keywords

  • HIV
  • Pregnancy
  • Tenofovir

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Nurutdinova, D., Onen, N. F., Hayes, E., Mondy, K., & Overton, E. T. (2008). Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Annals of Pharmacotherapy, 42(11), 1581-1585. https://doi.org/10.1345/aph.1L083

Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. / Nurutdinova, Diana; Onen, Nur F.; Hayes, Ericka; Mondy, Kristin; Overton, E. Turner.

In: Annals of Pharmacotherapy, Vol. 42, No. 11, 11.2008, p. 1581-1585.

Research output: Contribution to journalArticle

Nurutdinova, D, Onen, NF, Hayes, E, Mondy, K & Overton, ET 2008, 'Adverse effects of tenofovir use in HIV-infected pregnant women and their infants', Annals of Pharmacotherapy, vol. 42, no. 11, pp. 1581-1585. https://doi.org/10.1345/aph.1L083
Nurutdinova, Diana ; Onen, Nur F. ; Hayes, Ericka ; Mondy, Kristin ; Overton, E. Turner. / Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. In: Annals of Pharmacotherapy. 2008 ; Vol. 42, No. 11. pp. 1581-1585.
@article{cd0e331bd052447db94dc33048b4dd9d,
title = "Adverse effects of tenofovir use in HIV-infected pregnant women and their infants",
abstract = "BACKGROUND: Data regarding use of tenofovir disoproxil fumarate in HIV-infected pregnant women are limited. OBJECTIVE: To identify adverse effects of tenofovir use during pregnancy in HIV-infected women and their infants. METHODS: In a retrospective case series, the charts of 127 pregnant HIV-infected women who received highly active antiretroviral therapy (HAART) between 2001 and 2005 were reviewed. Those who received tenofovir during pregnancy were selected for this study. Each woman's chart was reviewed for clinical data and adverse events during the pregnancy; each infant's chart was reviewed for growth parameters from birth to 12 months. RESULTS: Fifteen HIV-infected women with limited treatment options were prescribed HAART containing tenofovir during 16 pregnancies. In utero tenofovir exposure was a median of 127 days (range 6-259). Tenofovir was well tolerated by all women throughout pregnancy. There were 15 successful deliveries occurring at a median (range) of 36 weeks (30-40), with a median birth weight of 3255 g (1135-3610). Complications, including 1 spontaneous abortion, occurred in 9 pregnancies and were not attributed to tenofovir. Eleven (73{\%}) women had abnormal laboratory results, including 6 who experienced grade 1 hemoglobin abnormalities: 4 of these women had preexisting anemia. Calculated glomerular filtration rate (calculated by Modification of Diet in Renal Disease equation) remained above 90 mL/min/1.73 m2 in all women, except one who had a transient decline. Fourteen infants demonstrated normal growth and development for weight and height at birth, as well as during the 12-month follow-up period; no congenital malformations were documented. Mother-to-child transmission of HIV was not observed in this cohort. CONCLUSIONS: Tenofovir was found to be a well-tolerated component of HAART in this small cohort. Longer-term assessment of tenofovir effects on childhood growth and larger prospective studies of tenofovir use in pregnant women are warranted.",
keywords = "HIV, Pregnancy, Tenofovir",
author = "Diana Nurutdinova and Onen, {Nur F.} and Ericka Hayes and Kristin Mondy and Overton, {E. Turner}",
year = "2008",
month = "11",
doi = "10.1345/aph.1L083",
language = "English (US)",
volume = "42",
pages = "1581--1585",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "11",

}

TY - JOUR

T1 - Adverse effects of tenofovir use in HIV-infected pregnant women and their infants

AU - Nurutdinova, Diana

AU - Onen, Nur F.

AU - Hayes, Ericka

AU - Mondy, Kristin

AU - Overton, E. Turner

PY - 2008/11

Y1 - 2008/11

N2 - BACKGROUND: Data regarding use of tenofovir disoproxil fumarate in HIV-infected pregnant women are limited. OBJECTIVE: To identify adverse effects of tenofovir use during pregnancy in HIV-infected women and their infants. METHODS: In a retrospective case series, the charts of 127 pregnant HIV-infected women who received highly active antiretroviral therapy (HAART) between 2001 and 2005 were reviewed. Those who received tenofovir during pregnancy were selected for this study. Each woman's chart was reviewed for clinical data and adverse events during the pregnancy; each infant's chart was reviewed for growth parameters from birth to 12 months. RESULTS: Fifteen HIV-infected women with limited treatment options were prescribed HAART containing tenofovir during 16 pregnancies. In utero tenofovir exposure was a median of 127 days (range 6-259). Tenofovir was well tolerated by all women throughout pregnancy. There were 15 successful deliveries occurring at a median (range) of 36 weeks (30-40), with a median birth weight of 3255 g (1135-3610). Complications, including 1 spontaneous abortion, occurred in 9 pregnancies and were not attributed to tenofovir. Eleven (73%) women had abnormal laboratory results, including 6 who experienced grade 1 hemoglobin abnormalities: 4 of these women had preexisting anemia. Calculated glomerular filtration rate (calculated by Modification of Diet in Renal Disease equation) remained above 90 mL/min/1.73 m2 in all women, except one who had a transient decline. Fourteen infants demonstrated normal growth and development for weight and height at birth, as well as during the 12-month follow-up period; no congenital malformations were documented. Mother-to-child transmission of HIV was not observed in this cohort. CONCLUSIONS: Tenofovir was found to be a well-tolerated component of HAART in this small cohort. Longer-term assessment of tenofovir effects on childhood growth and larger prospective studies of tenofovir use in pregnant women are warranted.

AB - BACKGROUND: Data regarding use of tenofovir disoproxil fumarate in HIV-infected pregnant women are limited. OBJECTIVE: To identify adverse effects of tenofovir use during pregnancy in HIV-infected women and their infants. METHODS: In a retrospective case series, the charts of 127 pregnant HIV-infected women who received highly active antiretroviral therapy (HAART) between 2001 and 2005 were reviewed. Those who received tenofovir during pregnancy were selected for this study. Each woman's chart was reviewed for clinical data and adverse events during the pregnancy; each infant's chart was reviewed for growth parameters from birth to 12 months. RESULTS: Fifteen HIV-infected women with limited treatment options were prescribed HAART containing tenofovir during 16 pregnancies. In utero tenofovir exposure was a median of 127 days (range 6-259). Tenofovir was well tolerated by all women throughout pregnancy. There were 15 successful deliveries occurring at a median (range) of 36 weeks (30-40), with a median birth weight of 3255 g (1135-3610). Complications, including 1 spontaneous abortion, occurred in 9 pregnancies and were not attributed to tenofovir. Eleven (73%) women had abnormal laboratory results, including 6 who experienced grade 1 hemoglobin abnormalities: 4 of these women had preexisting anemia. Calculated glomerular filtration rate (calculated by Modification of Diet in Renal Disease equation) remained above 90 mL/min/1.73 m2 in all women, except one who had a transient decline. Fourteen infants demonstrated normal growth and development for weight and height at birth, as well as during the 12-month follow-up period; no congenital malformations were documented. Mother-to-child transmission of HIV was not observed in this cohort. CONCLUSIONS: Tenofovir was found to be a well-tolerated component of HAART in this small cohort. Longer-term assessment of tenofovir effects on childhood growth and larger prospective studies of tenofovir use in pregnant women are warranted.

KW - HIV

KW - Pregnancy

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=55949090251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949090251&partnerID=8YFLogxK

U2 - 10.1345/aph.1L083

DO - 10.1345/aph.1L083

M3 - Article

C2 - 18957630

AN - SCOPUS:55949090251

VL - 42

SP - 1581

EP - 1585

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 11

ER -